• Documented physician-diagnosed asthma for at least 12 months prior to Visit 1

• Receiving 1 of the scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1

• Pre-bronchodilator FEV1 of ≥ 40% to \< 90% predicted normal value for adults.

• Documented reversibility to albuterol

• A documented history of at least one severe asthma exacerbation within 12 months before Visit 1

• ACQ-7 score ≥ 1.5 assessed at Visit 1

• Receiving inhaled SABA as needed prior to Visit 1 for at least 3 months

• Use of Sponsor-provided salbutamol sulfate inhalation aerosol as needed medication due to asthma symptoms on at least 3 days during the last week of the run-in period before Visit 2

⁃ Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited

⁃ Able to perform acceptable and reproducible PEF measurements as assessed by the investigator

⁃ BMI \< 40 kg/m2

⁃ Negative pregnancy test (urine at Visit 1) for female participants of childbearing potential

⁃ Women of childbearing potential must agree to prevent pregnancy

⁃ Compliance: must be willing to remain at the study site as required per protocol and complete all visit assessments